Bioprinting
Bioprinted disease models and transplantable tissues face different tests. Organovo describes tissue models for drug development. The FDA's record does not show approval of its designated bioprinted liver tissue. A 2030 timeline for printed organs is unproven, and so is the idea that using these models improves clinical results in drug development.
Research snapshot · updated Nov 12, 2026
State of the art (2026)
Bioprinting in 2026 is a commercial research-tools business wrapped around a still-preclinical therapeutic ambition. BICO Group (CELLINK), the category leader with over 30 per cent share, posted roughly $152M trailing revenue to end-2025 after a 2024 restructuring that cut staff and refocused on consumables and tissue models. The therapeutic frontier sits with Aspect Biosystems, which in January 2026 absorbed Novo Nordisk’s stem-cell islet and hypoimmune assets to lead a bioprinted islet replacement for type 1 diabetes – still IND-enabling, not in clinic. No bioprinted solid organ has FDA approval. The real near-term pull is FDA Modernization Act 2.0 demand for human tissue models that displace animal toxicology screens.
CELLINK BICO Group + Aspect commercial revenue sustains category economically
BICO Group (CELLINK) posted roughly $152M trailing revenue to end-2025 from bioprinters, bioinks and tissue models. Aspect Biosystems raised a $115M Series B in January 2025 (plus a 2026 Canadian government grant). Commercial revenue from tissue models, dermal and drug-screening services sustains the category economically while solid-organ therapeutics stay preclinical.
Aspect Biosystems islet programme is the leading therapeutic bioprinting bet
Aspect’s bioprinted islet for type 1 diabetes restores glucose control without chronic immunosuppression. Funded via the Novo Nordisk partnership ($75M initial 2023, up to $650M per-product milestones); in January 2026 Aspect took over Novo’s stem-cell islet and hypoimmune assets to lead development as Novo retreats from cell therapy. Still IND-enabling. Validates the bioprinted-cell-therapy pathway if it reaches clinic.
FDA rules on non-animal testing
A US law passed in December 2022, the FDA Modernization Act 2.0, allows drug developers to use non-animal methods to support an application to begin human trials. The FDA decides whether a method is acceptable case by case, depending on the method and what it is used to show. Bioprinted tissue models are one such method. We do not have confirmed evidence of how widely drug companies use them.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
9 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
4 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
61 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
6 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
8 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 20
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
9 updates
Thesis changelog
When our view changed, and why
Change our mind
5 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on Bioprinting has changed. All of it is in CanaryIQ.